|
|||
|
DRUGS & SUPPLEMENTS
|
Potassium Chloride 20 mEq in Sodium Chloride 0.9% in plastic container
How long you have been taking the medicine? |
Potassium Chloride 20 mEq in Sodium Chloride 0.9% in plastic container uses
- Indications and usage
- Contraindications
- Warnings
- Precautions
- Adverse reactions
- Overdosage
- Dosage and administration
- Instructions for use
- How supplied
- Im-0304
- Im-0305
INDICATIONS AND USAGE
These solutions are indicated in patients requiring parenteral administration of Potassium Chloride 20 mEq in Sodium Chloride 0.9% in plastic container and the replacement of extracellular losses of fluids and electrolytes with minimal carbohydrate calories.
CONTRAINDICATIONS
Solutions containing Potassium Chloride 20 mEq in Sodium Chloride 0.9% in plastic container are contraindicated in diseases where high potassium levels may be encountered.
Solutions containing lactate are NOT FOR USE IN THE TREATMENT OF LACTIC ACIDOSIS.
WARNINGS
Solutions containing calcium ions should not be administered simultaneously through the same administration set as blood because of the likelihood of coagulation.
Solutions which contain potassium ions should be used with great care, if at all, in patients with hyperkalemia, severe renal failure and in conditions in which potassium retention is present.
To avoid potassium intoxication, do not infuse these solutions rapidly. In patients with severe renal insufficiency or adrenal insufficiency, administration of Potassium Chloride 20 mEq in Sodium Chloride 0.9% in plastic container may cause potassium intoxication.
Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention.
In patients with diminished renal function, administration of solutions containing sodium or potassium ions may result in sodium or potassium retention.
Solutions containing lactate ions should be used with great care in patients with metabolic or respiratory alkalosis. The administration of lactate ions should be done with great care where there is an increased level or an impaired utilization of lactate ions, as in severe hepatic insufficiency.
The intravenous administration of these solutions can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema.
The risk of dilutional states is inversely proportional to the electrolyte concentration of administered parenteral solutions. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of such solutions.
PRECAUTIONS
Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.
Solutions containing dextrose should be used with caution in patients with known subclinical or overt diabetes mellitus.
Caution must be exercised in the administration of parenteral fluids, especially those containing sodium ions, to patients receiving corticosteroids or corticotropin.
Potassium replacement therapy should be guided primarily by serial electrocardiograms. Plasma potassium levels are not necessarily indicative of tissue potassium levels.
High plasma concentrations of potassium may cause death through cardiac depression, arrhythmias or arrest.
Potassium-containing solutions should be used with caution in the presence of cardiac disease, particularly in digitalized patients or in the presence of renal disease.
Solutions containing lactate ions should be used with caution as excess administration may result in metabolic alkalosis.
Care should be exercised to insure that the needle (or catheter) is well within the lumen of the vein and that extravasation does not occur.
Do not administer unless solution is clear and container is undamaged. Discard unused portion.
Pregnancy Category C. Animal reproduction studies have not been conducted with dextrose, Potassium Chloride 20 mEq in Sodium Chloride 0.9% in plastic container or Lactated Ringer’s Injection. It is also not known whether dextrose, Potassium Chloride 20 mEq in Sodium Chloride 0.9% in plastic container or Lactated Ringer’s Injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Dextrose, Potassium Chloride 20 mEq in Sodium Chloride 0.9% in plastic container or Lactated Ringer’s Injection should be given to a pregnant woman only if clearly needed.
Pediatric Use:
The safety and effectiveness in the pediatric population are based on the similarity of the clinical conditions of the pediatric and adult populations. In neonates or very small infants the volume of fluid may affect fluid and electrolyte balance.
Frequent monitoring of serum glucose concentrations is required when dextrose is prescribed to pediatric patients, particularly neonates and low birth weight infants.
In very low birth weight infants, excessive or rapid administration of dextrose injection may result in increased serum osmolality and possible intracerebral hemorrhage.
ADVERSE REACTIONS
Reactions which may occur because of the solutions or technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.
If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.
Nausea, vomiting, abdominal pain and diarrhea have been reported with potassium therapy. The signs and symptoms of potassium intoxication include paresthesias of the extremities, flaccid paralysis, listlessness, mental confusion, weakness and heaviness of the legs, hypotension, cardiac arrhythmias, heart block, electrocardiographic abnormalities such as disappearance of P waves, spreading and slurring of the QRS complex with development of a biphasic curve and cardiac arrest.
Potassium-containing solutions are intrinsically irritating to tissues. Therefore, extreme care should be taken to avoid perivascular infiltration. Local tissue necrosis and subsequent sloughing may result if extravasation occurs. Chemical phlebitis and venospasm have also been reported.
Should perivascular infiltration occur, I.V. administration at that site should be discontinued at once. Local infiltration of the affected area with procaine hydrochloride, 1%, to which hyaluronidase may be added, will often reduce venospasm and dilute the potassium remaining in the tissues locally. Local application of heat may also be helpful.
OVERDOSAGE
In the event of potassium overdosage, discontinue the infusion immediately and institute intensive corrective therapy to reduce serum potassium levels.
DOSAGE AND ADMINISTRATION
These solutions should be administered only by intravenous infusion and as directed by the physician. The dose and rate of injection are dependent upon the age, weight and clinical condition of the patient. If the serum potassium level is greater than 2.5 mEq/liter, potassium should be given at a rate not to exceed 10 mEq/hour in a concentration less than 30 mEq/liter. Somewhat faster rates and greater concentrations (usually up to 40 mEq/liter) of potassium may be indicated in patients with more severe potassium deficiency. The total 24-hour dose should not generally exceed 200 mEq of potassium.
As reported in the literature, the dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low birth weight infants, because of the increased risk of hyperglycemia/hypoglycemia.
Drug Interactions
Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store.
The presence of calcium limits their compatibility with certain drugs that form precipitates of calcium salts, and also prohibits their simultaneous infusion through the same administration set as blood because of the likelihood of coagulation.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
INSTRUCTIONS FOR USE
To Open
Tear outer wrap at notch and remove solution container. If supplemental medication is desired, follow directions below beforepreparing for administration. Some opacity of the plastic due to moistureabsorption during the sterilization process may be observed. Thisis normal and does not affect the solution quality or safety. Theopacity will diminish gradually.
To Add Medication
-
Prepare additive port.
-
Using aseptic technique and an additive deliveryneedle of appropriate length, puncture resealable additive port attarget area, inner diaphragm and inject. Withdraw needle after injectingmedication.
-
The additive port may be protected by covering withan additive cap.
-
Mix container contents thoroughly.
Preparation for Administration
(Use aseptic technique)
-
Close flow control clamp of administration set.
-
Remove cover from outlet port at bottom of container.
-
Insert piercing pin of administration set into portwith a twisting motion until the set is firmly seated. NOTE: See full directions on administrationset carton.
-
Suspend container from hanger.
-
Squeeze and release drip chamber to establish properfluid level in chamber.
-
Open flow control clamp and clear air from set. Closeclamp.
-
Attach set to venipuncture device. If device is notindwelling, prime and make venipuncture.
-
Regulate rate of administration with flow controlclamp.
WARNING: Do not use flexiblecontainer in series connections.
HOW SUPPLIED
Intravenous solutions with Potassium Chloride 20 mEq in Sodium Chloride 0.9% in plastic container (I.V. solution with KCl) are supplied in single-dose flexible plastic containers. See Table:
Potassium Chloride 20 mEq in Sodium Chloride 0.9% in plastic container
in Lactated Ringer’s
and 5% Dextrose
Injection, USP
| List No. | mEq Potassium Added | Size (mL) | COMPOSITION (g/L) | Calculated Osmolarity (mOsmol/L) | ||||
| Dextrose, Hydrous | Potassium Chloride | Sodium Chloride | Sodium Lactate, Anhydrous | Calcium Chloride Dihydrate | ||||
| 7111 7113 | 20 mEq 40 mEq | 1000 1000 | 50 50 | 1.79 3.28 | 6 6 | 3.1 3.1 | 0.2 0.2 | 563 604 |
Potassium Chloride 20 mEq in Sodium Chloride 0.9% in plastic container
in Lactated Ringer’s
and 5% Dextrose
Injection, USP (Continued)
| pH | Approx. Ionic Concentrations (mEq/L) | Approx. kcal/L | ||||
| Calcium (Ca++) | Sodium (Na+) | Potassium (K+) | Chloride (Cl¯) | Lactate | ||
| 4.9 (3.5 to 6.5) 4.9 (3.5 to 6.5) | 2.7 2.7 | 130 130 | 24 44 | 129 149 | 28 28 | 179 179 |
May contain HCl for pH adjustment.
Store at 20 to 25°C (68 to 77°F). Protect from freezing.
Revised: October, 2006
EN-1319 Printed in USA
Hospira, Inc., Lake Forest, IL 60045 USA
IM-0304
IM-0305
Potassium Chloride 20 mEq in Sodium Chloride 0.9% in plastic container pharmaceutical active ingredients containing related brand and generic drugs:
Potassium Chloride 20 mEq in Sodium Chloride 0.9% in plastic container available forms, composition, doses:
Composition is the list of ingredients which combinedly form a medicine. Both active ingredients and inactive ingredients form the composition. The active ingredient gives the desired therapeutic effect whereas the inactive ingredient helps in making the medicine stable.
Doses are various strengths of the medicine like 10mg, 20mg, 30mg and so on. Each medicine comes in various doses which is decided by the manufacturer, that is, pharmaceutical company. The dose is decided on the severity of the symptom or disease.